Explore what’s happening here
Sumitomo Dainippon Pharma Oncology (SDP Oncology) is advancing innovative science and transforming new discoveries into meaningful therapeutic options for patients with cancer. To learn more about our most recent discoveries, commercial efforts, and cancer care projects, see our press releases and other news below.
To contact our media relations staff, click here.
Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed with TP-1454 in Patients with Advanced Solid Tumors
Sumitomo Dainippon Pharma Oncology, Inc., a developer of novel cancer therapeutics, today announced that the first patient has been dosed with TP-1454, an investigational small-molecule pyruvate kinase M2 isoform (PKM2) activator, administered alone and in combination with ipilimumab and nivolumab, in a Phase 1/1b study in patients with advanced metastatic or progressive solid tumors.
Sumitomo Dainippon Pharma Oncology Presents Findings from Phase 1 Clinical Study Evaluating Investigational Agent Dubermatinib in Patients with Advanced Solid Tumors at ESMO 2020 Virtual Annual Congress
Sumitomo Dainippon Pharma Oncology, Inc., a developer of novel cancer therapeutics, today presented new data from the ongoing Phase 1 study evaluating dubermatinib (TP-0903), an AXL kinase inhibitor, in patients with advanced solid tumors. These results were presented during a mini-oral presentation at the European Society of Medical Oncology (ESMO) 2020 Virtual Annual Congress, being held September 19-21, 2020.
Sumitomo Dainippon Pharma Oncology to Present New Data Evaluating Investigational Agent Dubermatinib at ESMO 2020 Virtual Annual Congress
Sumitomo Dainippon Pharma Oncology, Inc., a developer of novel cancer therapeutics, today announced that new data evaluating the oral investigational agent dubermatinib (TP-0903), an AXL kinase inhibitor, will be presented at the European Society of Medical Oncology (ESMO) 2020 Virtual Annual Congress, being held September 19-21, 2020. Data will be shared during the Developmental Therapeutics Mini-Oral Presentation and include findings from a Phase 1 study evaluating the safety, pharmacokinetics, pharmacodynamics and clinical activity of dubermatinib in patients with advanced solid tumors.
Japan’s Sumitomo merges oncology arms Tolero Pharma, Boston Biomedical
Leslie Shaffer / Deal Street Asia
An experienced biotech is stitched together from transpacific parts, with 265 staffers and a focus on ‘new biology’
John Carroll / Endpoints News
Sumitomo merges U.S. biotechs to create oncology division
Nick Paul Taylor / FierceBiotech
Sumitomo Dainippon Pharma Oncology Announces Its Formation Through Merger of Tolero and Boston Biomedical
Sumitomo Dainippon Pharma Oncology Advances Meaningful Therapies for Cancer Patients through Innovative Drug Discovery, Research and Development.
By clicking on a link on this page, you may exit the SDP Oncology website for a third party website. Links which take you out of the SDP Oncology website are not under the control of SDP Oncology, and SDP Oncology is not responsible for the contents of any such site or any further links from such site. SDP Oncology is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by SDP Oncology. The website that you have requested also may not be optimized for your screen size.